Prognosis
Moderna Vaccine Produces Antibodies in Trial of Older People
- New data from early-stage trial presented to CDC advisors
- High antibody levels to virus seen in older adults after shots
This article is for subscribers only.
Moderna Inc. presented new safety data from an early trial that provides the first evidence that its Covid-19 vaccine stimulates the immune systems of older people.
In a phase 1 trial, Moderna’s coronavirus vaccine produced “consistently high levels” of neutralizing antibodies -- a key component of the body’s protective response -- in older adults, the company said in a statement. Antibody levels in people more than 55 years old were comparable to those seen in younger adults, the company said.